Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 21:02:10 29/04/2024 BST			5-day change	1st Jan Change
160.4 ^USD	+0.46%		-4.15%	+3.85%

05:26pm	BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	MT
02:52pm	Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	04:26pm	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	01:52pm	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	01:31pm	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	04-19	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	03-27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	03-22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	03-21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	03-15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	02-26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	02-15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	02-06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	02-06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	02-05	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	02-05	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	02-05	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	02-05	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	02-05	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	02-05	MT
Raymond James Adjusts Price Target on AbbVie to $189 From $181, Maintains Outperform Rating	02-05	MT
Powell, the paper tiger	02-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Analyst Reco.

Filters